Mylan announced last week that it will join forces with Pfizer’s Established Products division in Japan to sell generic drugs. Pfizer will be responsible for marketing, while Mylan does product development and manufacturing. The collaboration will apparently involve at least 350 existing marketed products,...
Actavis finally ties the knot with Bioton
Actavis announced earlier this week that it had finally tied up an agreement with the Polish company Bioton, having first mooted it in September 2010. According to the press release, Actavis will pay Bioton €22.25m immediately and a further €33.25m in instalments, if certain...
Watson partners Amgen and takes a leap forwards in biosimilars
Watson announced yesterday that it is tying up with Amgen to develop biosimilars of ‘several’ oncology monoclonal antibodies. Under the terms of the deal, Amgen will have the main responsibility for the actual development work, as well as manufacture and initial commercialisation (under a...
Competition in biosimilars hots up (slightly) as Richter and Stada join foces
Richter and Stada announced today that they are combining their efforts in the field of mAbs, with a view to developing two key products, rituximab and trastuzumab, in a cost-effective manner. Under the terms of their agreement, Stada has paid Richter an up-front fee...
Playing with the big boys: Teva and P&G join forces in OTC
Teva and Proctor and Gamble (P&G) jointly announced today that they intend to create a joint venture in OTC. Owned 51% by P&G and 49% by Teva, the jv will encompass the whole of Teva’s global OTC business (which is split roughly 50:50 between...
Bioton and Actavis get closer to a deal on insulin
Bioton announced on March 7th that it had signed a Term Sheet with Actavis covering the two companies’ planned co-operation to develop Bioton’s portfolio of insulins, which includes insulin analogues. According to the press release, the two companies will set up a JV that...
Watson invests in moksha8 and expands its presence in LatAm
Watson announced yesterday that it has invested $30m to take a stake in moksha8, a PE-backed pharmaceutical company based in Sao Paolo, Brazil. It has also committed to investing a further $20m, contingent on moksha8 being able to make certain specified product acquisitions over...
Actavis makes a belated move into biosimilars
Actavis said today that it is considering the purchase of a 51% stake in Biopartners, the Swiss subsidiary of the quoted Polish company Bioton. The cost of this is to be determined, but will depend on the future investment needs of the business –...
GSK extends the Aspen model into Asia, buys into Dong A
GSK announced this morning that it has concluded a strategic agreement with Dong-A of South Korea. As with the deal that GSK did with Aspen last year, there are various elements to the agreement, one of which involves GSK taking a 9.9% equity stake...